p52-p36- GAP Vaccine(SCRI)(p52-p36- GAP Vaccine(SCRI))

概要

基本信息

药物类型

预防性疫苗

别名-

靶点-

作用机制

免疫刺激剂

治疗领域

感染

在研适应症-

非在研适应症

疟疾

原研机构

Seattle Children's Research Institute

在研机构-

非在研机构

Seattle Children's Research Institute

最高研发阶段终止临床1/2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

1

项与 p52-p36- GAP Vaccine(SCRI) 相关的临床试验

NCT01024686

/ Terminated临床1/2期IIT

Phase 1/2a Trial to Assess the Safety, Immunogenicity and Efficacy of Genetically-attenuated Plasmodium Falciparum Parasites p52-/p36- (GAP) Vaccine, Administered by Bite of Infected Anopheles Mosquito to Malaria-naïve Adults Living in the United States.

The purpose of this study is to assess safety and tolerability of escalating doses of a genetically attenuated parasite malaria vaccine (p52-/p36- GAP vaccine) in healthy malaria-naive adults. The study will also assess preliminary efficacy of p52-/p36- GAP vaccine following primary experimental challenge with P. falciparum sporozoites. Lastly, the study will assess immunogenicity of p52-/p36- GAP in malaria-naïve healthy adults and preliminary efficacy of p52-/p36- GAP vaccine following primary experimental re-challenge with P. falciparum sporozoites.

开始日期2010-03-01

申办/合作机构

Seattle Children's Research Institute

100 项与 p52-p36- GAP Vaccine(SCRI) 相关的临床结果

登录后查看更多信息

100 项与 p52-p36- GAP Vaccine(SCRI) 相关的转化医学

登录后查看更多信息

100 项与 p52-p36- GAP Vaccine(SCRI) 相关的专利（医药）

登录后查看更多信息

100 项与 p52-p36- GAP Vaccine(SCRI) 相关的药物交易

登录后查看更多信息